The shadow of generic competition has long loomed above copyright’s iconic drug, Viagra, triggering questions about the outlook of similar medicinal portfolios. While early years saw substantial gains, the exclusivity end has opened the door for less expensive alternatives, potentially diminishing revenue and posing a significant danger for share